Educational research resource. Contains sponsored placement — see editorial disclosure.

Condition evidence map

Obesity

Research evidence map for obesity: the SCALE, STEP, SURMOUNT and Phase 2 retatrutide weight-management programmes, dose-response and discontinuation data, and UK MHRA/NICE positioning.

By Metabolic Peptides Editorial TeamReviewed by Scientific Review PanelLast updated

Research context

Obesity (BMI ≥30, or ≥27.5 in South Asian populations) affects roughly 28% of adults in England, with a further ~38% overweight; the NHS estimated the direct cost of overweight and obesity at £6.1 billion a year in 2023. Historically resistant to durable pharmacotherapy, obesity has been transformed by the incretin class across four programmes: SCALE (liraglutide 3.0 mg, 2015; ~8.0% vs 2.6% placebo at 56 weeks), STEP (semaglutide 2.4 mg, 2021–22; STEP-1 ~14.9% at 68 weeks), SURMOUNT (tirzepatide, 2022–23; SURMOUNT-1 ~15.0/19.5/20.9% at the 5/10/15 mg doses over 72 weeks), and the Phase 2 retatrutide trial (2023; ~24.2% at 12 mg over 48 weeks — the largest mean reduction reported at publication, with no apparent plateau). STEP-4 and SURMOUNT-4 characterise weight regain after discontinuation; SELECT extended the evidence to cardiovascular outcomes.

Why this matters metabolically

GLP-1 receptors are broadly expressed — hypothalamus, brainstem, vagal afferents, gastric smooth muscle, pancreatic islets — so agonism reduces energy intake through central appetite/satiety signalling and slowed gastric emptying, cutting ad libitum intake by roughly 500–800 kcal/day at therapeutic doses. Adding GIP agonism (tirzepatide) contributes adipose-tissue effects (lipolysis, adiponectin, macrophage polarisation), and adding glucagon agonism (retatrutide) raises resting energy expenditure via hepatic fatty-acid oxidation — a plausible third additive axis. This multi-node pharmacology distinguishes the class from earlier single-pathway weight-loss agents (sibutramine, rimonabant).

FAQs

What is the maximum mean weight reduction documented in a phase 3 obesity trial?
As of 2025, tirzepatide 15 mg produced the largest mean weight reduction in a completed phase 3 RCT: approximately 22.5% at 72 weeks in SURMOUNT-1. Among GLP-1 monoagonists, semaglutide 2.4 mg achieved approximately 14.9% in STEP-1. The Phase 2 retatrutide trial reported approximately 24.2% at 48 weeks, but this was an early-phase trial with a smaller sample and shorter duration.
How does the STEP programme differ from SURMOUNT?
STEP (STEP-1 through STEP-8) evaluated semaglutide 2.4 mg weekly across diverse populations — without T2D (STEP-1), with T2D (STEP-2), maintenance (STEP-3/4), adolescents, and with cardiovascular disease (SELECT). SURMOUNT-1 to -4 evaluated tirzepatide 5/10/15 mg in adults without T2D, with T2D (SURMOUNT-2), with a dietary lead-in (SURMOUNT-3), and for weight maintenance (SURMOUNT-4).
What were the SCALE trials and what did they show?
SCALE was a programme of phase 3 trials for liraglutide 3.0 mg (Saxenda) in obesity. SCALE Obesity and Prediabetes showed a mean weight reduction of approximately 8.0% at 56 weeks versus 2.6% with placebo — substantially lower than the later STEP and SURMOUNT results, reflecting daily dosing, lower receptor binding affinity and the absence of GIP co-agonism.
What does the retatrutide Phase 2 data suggest about weight-reduction trajectories?
The Phase 2 retatrutide trial (NEJM 2023) reported approximately 24.2% mean weight reduction at 12 mg weekly over 48 weeks, with the weight-loss curve not yet plateauing — suggesting continued divergence with longer treatment and driving interest in whether triple-receptor agonism (GLP-1/GIP/glucagon) yields a different weight set-point than dual agonism. Phase 3 (TRIUMPH) is the confirmatory test.
How much weight regain occurs after stopping semaglutide?
STEP-4 randomised participants who had lost weight on semaglutide 2.4 mg to continue or switch to placebo. Those switched to placebo regained approximately two-thirds of their lost weight over the subsequent 48-week withdrawal period, with cardiometabolic improvements largely reversing — underpinning the framing of obesity as a chronic condition requiring long-term management rather than a short course.
What the obesity evidence does not prove
  • Trial-cohort mean weight reductions do not predict any individual's response.
  • Weight-reduction magnitude does not by itself establish cardiovascular, hepatic or long-term outcome benefit.
  • Predominantly female, White trial populations may not generalise uniformly across UK ethnicities.
  • Absence of beyond-5-year safety and weight-maintenance data is an open limitation for the whole class.

Related mechanisms

Related peptide profiles

Related trials

Related safety signals

Related conditions

Source quality

Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.

Last reviewed 25 July 2026 · Obesity evidence map · Metabolic Peptides editorial team